Document:

Exhibit 4.6

 

NEITHER
this Warrant NOR THE SECURITIES INTO WHICH this Warrant is EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED OR APPLICABLE STATE SECURITIES LAWS. Neither this Warrant nor such securities MAY BE OFFERED FOR SALE, SOLD, TRANSFERRED
OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY’S COUNSEL, THAT REGISTRATION IS
NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. ANY TRANSFEREE
OF THIS WARRANT SHOULD CAREFULLY REVIEW THE TERMS OF THIS WARRANT.

 

SCOPUS
BIOPHARMA Inc.

 

Warrant
To Purchase Common Stock

 

Warrant No. Y-1

Number of Shares of Common Stock: Up to
450,000

Date of Issuance: October 3, 2018 (“Issuance
Date”)

 

Scopus BioPharma Inc.,
a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Yissum Research Development Corporation of the Hebrew University
of Jerusalem, Ltd., the registered holder hereof or its permitted assigns (the “Holder”), is entitled,
subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon
surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer
or replacement hereof, the “Warrant”), at any time or times on or after the date hereof, but not after
11:59 p.m., Delaware time, on October 3, 2025, up to Four Hundred Fifty Thousand (450,000) fully paid, validly issued and nonassessable
shares (the “Warrant Shares”) of the Company’s common stock, $0.001 par value (the “Common
Stock”). References in this Warrant to “Sections” shall be to Sections of this Warrant unless otherwise
specifically provided. This Warrant is being issued as additional consideration to the Holder in connection with the execution
by the Company and the Holder of two separate Memorandum of Understandings (each, a “MOU”), one MOU
having Alexander Binshtok as its primary researcher (the “AB MOU”), and the other having Dimitri Tsvelikhovsky
as its primary researcher (the “DT MOU”).

 

		1.	Exercise of Warrant

 

(a)       Number
of Warrant Shares.

 

(i)       Upon
issuance this Warrant is exercisable for 50,000 Warrant Shares.

 

(ii)       For
the initial license agreement which is executed between the Company and Holder under the AB MOU and for up to the initial three
license agreements executed between the Company and Holder under the DT MOU, this Warrant will become exercisable for an additional
fifty thousand (50,000) Warrant Shares for each such license agreement for a maximum total of up to 200,000 Warrant Shares.

 

    1 

     

    

 

(iii)       Relating
to the license agreements referenced in clause (ii) above, if each of such license agreements is executed within one hundred fifty
(150) days from the date that the Company notifies (“Notice”) the Holder under an MOU that it desires
to obtain a license, this Warrant will become exercisable for an additional number of Warrant Shares as follows:

 

	If the license is executed within 30 days of Notice	50,000 Warrant Shares
	 	 
	If the license is executed after 30 days and  on or before 60 days from notice	40,000 Warrant Shares
	 	 
	If the license is executed after 60 days and on or before 90 days from notice	30,000 Warrant Shares
	 	 
	If the license is executed after 90 days and on or before 120 days from notice	20,000 Warrant Shares
	 	 
	If the license is executed after 120 days and on or before 150 days from notice	10,000 Warrant Shares

 

 

(b)       Mechanics
of Exercise. Subject to the terms and conditions hereof, this Warrant may be exercised by the Holder on any day on or after
the date hereof, in whole or in part, by (i) delivery to the Company of a written notice, in the form attached hereto as
Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant, (ii)
surrender of this Warrant and (iii) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the
number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”)
in cash or by wire transfer of immediately available funds.

 

(c)       Certificates
for Warrant Shares. The rights under this Warrant shall be deemed to have been exercised and the Warrant Shares issuable upon
such exercise shall be deemed to have been issued immediately prior to the close of business on the date this Warrant is exercised
in accordance with its terms, and the Person entitled to receive the Warrant Shares issuable upon such exercise shall be treated
for all purposes as the holder of record of such Warrant Shares as of the close of business on such date. Upon the exercise of
this Warrant in compliance with the provisions of Section 1(a), the Company shall deliver to the Holder one or more certificates
for the number of Warrant Shares so purchased.

 

(d)       Issuance
of Warrant for Balance of Warrant Shares. If this Warrant is submitted in connection with any exercise and the number of Warrant
Shares represented by this Warrant is greater than the number of Warrant Shares with respect to which this Warrant is exercised,
then the Company shall as soon as practicable, and in any event within thirty (30) days of the Exercise Notice, issue a new Warrant
(in accordance with Section 4(d)) representing the right to purchase the number of Warrant Shares purchasable immediately
prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.
No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common
Stock to be issued shall be rounded up to the nearest whole number.

 

(e)       Exercise
Price. For purposes of this Warrant, “Exercise Price” means $1.50 per share, subject to adjustment
as provided herein.

 

    2 

     

    

 

(f)       Insufficient
Authorized Shares. The Company agrees during the term the rights under this Warrant are exercisable to reserve and keep available
from its authorized and unissued shares of Common Stock solely for the purpose of effecting the exercise of this Warrant such
number of shares as shall from time to time be sufficient to effect the exercise of the rights under this Warrant; and if at any
time the number of authorized but unissued shares of Common Stock shall not be sufficient for purposes of the exercise of this
Warrant in accordance with its terms, the Company will use all reasonable efforts to take such corporate action as may be necessary
to increase its authorized and unissued shares of its Common Stock to a number of shares as shall be sufficient for such purposes.
The Company represents and warrants that all shares that may be issued upon the exercise of this Warrant will, when issued in
accordance with the terms hereof, be validly issued, fully paid and nonassessable.

 

2.       Adjustment
of Exercise Price

 

(a)       Adjustment
for Stock Splits, Stock Dividends, Etc. If, at any time on or after the date hereof, the number of outstanding shares of Common
Stock is increased by a stock split, stock dividend, reclassification or other similar event, the Exercise Price shall be proportionately
reduced, or if the number of outstanding shares of Common Stock is decreased by a reverse stock split, combination or reclassification
of shares, or other similar event, the Exercise Price shall be proportionately increased.

 

(b)       Adjustment
Due to Merger, Consolidation, Etc. If, at any time after the date hereof, there shall be (i) any reclassification or
change of the outstanding shares of Common Stock (other than a change in par value, or from par value to no par value, or from
no par value to par value, or as a result of a subdivision or combination), (ii) any consolidation or merger of the Company
with any other entity (other than a merger in which the Company is the surviving or continuing entity and its capital stock is
unchanged), (iii) any sale or transfer of all or substantially all of the assets of the Company, or (iv) any share exchange
pursuant to which all of the outstanding shares of Common Stock are converted into other securities or property (each of (i) -
(iv) above being a “Corporate Change”), then the Holder shall thereafter have the right to receive
upon exercise of this Warrant, in lieu of the shares of Common Stock otherwise issuable, such shares of stock, securities and/or
other property as would have been issued or payable in such Corporate Change with respect to or in exchange for the number of
shares of Common Stock which would have been issuable upon such exercise had such Corporate Change not taken place.

 

(c)       Notice
of Adjustments. Upon the occurrence of each adjustment or readjustment of the Exercise Price pursuant to this Section 2,
the Company shall promptly compute such adjustment or readjustment and prepare and furnish to the Holder a certificate setting
forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based.

 

    3 

     

    

  

3.       Warrant
Holder Not Deemed a Shareholder; Compliance with Securities Laws.

 

(a)       Warrant
Holder Not Deemed a Shareholder. Except as otherwise specifically provided herein, the
Holder, solely in Holder’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be
deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to
confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a shareholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription
rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive
upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities, including the Warrant Shares or as a shareholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company.

 

(b)       Securities
Law Legend. The Warrant Shares shall (unless otherwise permitted by the provisions of this Warrant) be stamped or imprinted
with a legend substantially similar to the following (in addition to any legend required by state securities laws):

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND ARE
“RESTRICTED SECURITIES” AS THAT TERM IS DEFINED IN RULE 144 UNDER THE ACT. THE SHARES MAY NOT BE OFFERED FOR SALE,
SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR PURSUANT TO AN EXEMPTION
FROM REGISTRATION UNDER THE ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY.

 

(c)       Instructions
Regarding Transfer Restrictions. The Holder consents to the Company making a notation on its records and giving instructions
to any transfer agent in order to implement the restrictions on transfer established in Section 4(a).

 

(d)       Removal
of Legend. The legend referring to federal and state securities laws identified in Section 3(b) stamped on a certificate
evidencing the Warrant Shares and the stock transfer instructions and record notations with respect to such securities shall be
removed and the Company shall issue a certificate without such legend to the holder of such securities if (i) such securities
are registered under the Securities Act of 1933, as amended, or (ii) such holder provides the Company with an opinion of
counsel reasonably acceptable to the Company’s counsel to the effect that a sale or transfer of such securities may be made
without registration or qualification. Removal of the legend, however, shall not, in and of itself, result in the Warrant Shares
being transferable hereunder if not otherwise transferable under this Warrant.

 

    4 

     

    

 

4.       Transfer;
Reissuance of Warrants; Lock-Up

 

(a)       Transfer
of Warrant. Subject to the Company’s consent, this Warrant may be transferred. Upon any such transfer, the Holder shall
surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new
Warrant (in accordance with Section 4(d)), registered as the Holder may request, representing the right to purchase the
number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying
this Warrant is being transferred, a new Warrant (in accordance with Section 4(d)) to the Holder representing the right
to purchase the number of Warrant Shares not being transferred. Any restriction on transfer shall terminate on the expiration
of the Restricted Period (as defined in paragraph (e) below).

 

(b)       Lost,
Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking
by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant,
the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 4(d)) representing the right
to purchase the Warrant Shares then underlying this Warrant.

 

(c)       Exchangeable
for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the
Company, for a new Warrant or Warrants (in accordance with Section 4(d)) representing in the aggregate the right to purchase
the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such
portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however,
that no Warrants for fractional shares of Common Stock shall be given.

 

(d)       Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to
purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section
4(a) or Section 4(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common
Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares
then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same
as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

 

    5 

     

    

 

(e)       Lock-Up
Restriction. The Warrant and Warrant Shares (collectively, Warrant Securities”) may not be sold, transferred,
assigned, pledged, hypothecated, mortgaged, or otherwise disposed of or made subject to any lien or security interest, during the
Restricted Period (as defined below) without the consent of the Company in its sole discretion. The “Restricted Period”
means the period commencing on the date hereof and continuing until the first Business Day following the three (3) year anniversary
of the Initial Trading Date; provided, however, if such Business Day is a Friday, then the Restricted Period shall expire on the
next Business Day; provided further, that the Company may elect to release Holder from this lock-up at any time or from time to
time for any reason or no reason with respect to any or all of such Warrant Securities. For purposes hereof, “Business
Day” means a day that banks in New York City are open for business. No such release shall be deemed to obligate the
Company to grant any future releases to Holder. In addition, Holder agrees to execute any lock-up agreement required by the lead
underwriter in connection with the Company’s Initial Public Offering that the Company may conduct while Holder holds any
of the Warrant Securities; provided, that any such agreement is consistent with the form of lock-up agreements generally required
by underwriters. For purposes hereof, the “Initial Trading Date” shall mean the first date upon which
shares of the Company’s capital stock trade on a national securities exchange or any quotation service that requires as a
condition for trading that such shares be registered under the Securities Exchange Act of 1934, as amended, and the “Initial
Public Offering” shall mean the initial registered or qualified public offering of the Company’s capital stock
under the Securities Act which has been declared effective or qualified by the Securities Exchange Commission and such shares of
capital stock have been registered under the Securities Exchange Act of 1934, as amended.

 

5.       Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Warrant must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally, (ii) upon receipt, when
sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party) or email, or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to
the party to receive the same. The addresses and facsimile numbers for such communications shall be:

 

If to the Company:

 

Scopus BioPharma Inc.

c/o HCFP Inc.

420 Lexington Avenue

Suite 300

New York, New York 10170

Attn: Robert J. Gibson

rjg@hcfp.com

With a copy (for informational
purposes only) to:

 

Greenberg Traurig,
LLP

1750 Tysons Boulevard

Suite 1000

McLean, VA 22102

Facsimile:(703) 714-8359

wishnerm@gtlaw.com

Attention: Mark Wishner, Esq.

 

If to the Holder, to
its address and facsimile number set forth on the signature page to this Warrant or to such other address and/or facsimile number
and/or to the attention of such other Person as the Holder has specified by written notice given to the Company five (5) days
prior to the effectiveness of such change.

 

    6 

     

    

 

6.       Amendment.
Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein
prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent
of the Holder for any amendment that is adverse to Holder.

 

7.       Governing
Law; Venue. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by the internal laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of Delaware or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of Delaware. The Company consents to and irrevocably submits to the jurisdiction of the Delaware Court of
Chancery (or if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal
court sitting in the State of Delaware), and agrees that any dispute respecting this Warrant shall be submitted to and determined
by such court. Final judgment of the Delaware Court of Chancery (or if the Delaware Court of Chancery declines to accept jurisdiction
over a particular matter, any state or federal court sitting in the State of Delaware) shall be conclusive and binding on the
Company and may be enforced in any court in which the Company is subject to jurisdiction by a suit upon such judgment.

 

8.       Construction;
Headings. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against
any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or
affect the interpretation of, this Warrant.

 

9.       Remedies.
The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available at law or in equity
(including a decree of specific performance and/or other injunctive relief). The Company acknowledges that a breach by it of its
obligations hereunder may cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.
The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition
to all other available remedies, to an injunction restraining any breach, without any bond or other security being required.

 

10.       Severability.
If any provision of this Warrant becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Warrant, and
such illegal, unenforceable or void provision shall be replaced with a valid and enforceable provision that will achieve, to the
extent possible, the same economic, business and other purposes of the illegal, unenforceable or void provision. The balance of
this Warrant shall be enforceable in accordance with its terms.

 

[Signature Page Follows]

 

    7 

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

 

	 	SCOPUS BIOPHARMA INC.
	 	 
	 	By:	/s/
    Joshua R. Lamstein                                                   
	 	Name: Joshua R. Lamstein
	 	Title: Co-Chairman of the Board of Directors

 

Acknowledged
and Agreed:

 

YISSUM RESEARCH DEVELOPMENT CORPORATION OF THE

HEBREW UNIVERSITY OF JERUSELUM, LTD.

 

	By:	/s/     Dr.     Yavon
    Daniely                           
	Name:	 Dr. Yavon Daniely

 

Address:

Hi Tech Park

Edmond J. Safra Campus

GivatRam

Jerusalem 91390 Israel

 

[Signature
Page to Warrant to Purchase Common Stock]

 

     

     

    

 

EXHIBIT A

 

EXERCISE NOTICE

 

[To be executed by the registered Holder
in order 

to exercise this Warrant to Purchase Common Stock]

 

SCOPUS
BIOPHARMA Inc.

 

The undersigned holder
hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant Shares”)
of Scopus BioPharma Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant
to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall
have the respective meanings set forth in the Warrant.

 

1.       Payment
of Exercise Price. In the event that the Holder has elected a Cash Exercise with respect to some or all of the Warrant Shares
to be issued pursuant hereto, the Holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company
in accordance with the terms of the Warrant.

 

2.       Delivery
of Warrant Shares. The Company shall deliver to the undersigned Registered Holder __________ Warrant Shares in accordance
with the terms of the Warrant.

 

Date: _______________ __, ______

 

	 
	Name of Registered Holder

 

	By:	                                              
	 	Name:
	 	Title:Exhibit 10.7

 

SCIENTIFIC ADVISORY BOARD MEMBER
AGREEMENT

 

This Scientific Advisory
Board Member Agreement (the “Agreement”) is made as of this ___ day of ____________, 201__ (the “Effective
Date”) by and between Scopus BioPharma Inc. (the “Company”), having a principal place of
business at 420 Lexington Avenue, Suite 300, New York, New York 10170, and _______________________ (the “Member”)
an individual residing at ________________________________.

 

1.           Engagement.
Upon the terms and conditions contained in this Agreement, the Company hereby engages Member, and Member hereby accepts the engagement,
and agrees to consult with the Company in his/her capacity as a member of the Company’s Scientific Advisory Board (the “SAB”)
on the terms and conditions set forth in this Agreement.

 

2.           SAB
Participation. During the Term of this Agreement (as defined in Section 5 below), the Member shall serve a member of
the SAB. The Member shall be available on a reasonable basis for meetings of the SAB and will perform the duties and obligations
described hereunder in accordance with accepted professional and ethical standards. The Member may be requested to participate
in up to four (4) meetings of the SAB each calendar year one of which may be conducted in person. The Company shall provide Member
with reasonable advance notice of such SAB meetings. The number and frequency of meetings of the SAB shall be determined by the
Company from time to time and are expected to be conducted by phone or at the Company’s offices and other locations selected
by the Company from time to time. The Company may also request the Member from time to time to speak on behalf of the Company at
academic, scientific or business conferences or in other public settings. Member also agrees to be available from time to time
to consult with executives of the Company and Company board of director members, either telephonically or in person, on issues
concerning the Company, including its research, possible products and personnel. In addition, from time to time, the Company may
request the Member to provide consulting services for the Company for compensation and on the other material terms and conditions
of which are to be agreed to by the Company and the Member and set forth in a separate agreement.

 

3.            Compensation.

 

(a)       The
Company grants the Member a non-qualified stock option (the “Option”) to purchase ____________
(____________) shares of the Company’s common stock, $0.001
par value per share (the “Common Stock”) pursuant to the Stock Option Agreement attached hereto as Exhibit
A (the “Option Agreement”) at an exercise price of $____________ per
share. The terms and conditions of the Option are as set forth in the Option Agreement. 

 

4.             Expenses.
The Company shall reimburse the Member for all pre-approved travel and other out-of-pocket expenses actually and reasonably incurred
by the Member in connection with attending SAB meetings in person and for the speeches or other public appearances made by the
Member as referenced in Section 2 above. Reimbursement of such expenses shall be made upon presentation of expense statements,
vouchers, and other supporting documentation in such form and containing such information as the Company may from time to time
request.

 

5.                Term.
The term of Member’s engagement (the “Term”) shall have been deemed to commence on the Effective
Date and terminate on the third anniversary of the Effective Date through the third anniversary of the Effective Date unless terminated
earlier as hereinafter provided, unless extended by agreement of the Company and Member.

 

     

     

    

 

6.            Independent
Contractor. The Member is an independent contractor and not an employee of the Company and neither the Company nor the Member
shall have the power to bind the other, contractually or otherwise and the Member shall be solely responsible for any and all state
and federal taxes, due in respect of the compensation paid to Member by the Company pursuant to this Agreement.

 

7.            Confidentiality
& Inventions.

 

(a)       “Proprietary
Information” includes all confidential and proprietary information and trade or secrets of the Company, including
but not limited to any technical, scientific, regulatory or business information and materials, clinical data and derivatives thereof,
clinical and scientific documents, protocols, data collection tools, study reports, product architecture, designs, drawing and
functions, software, methods of interpretation of images, programs, and manuals, customer or vendor lists, costs, profits, sales,
marketing strategies, distribution procedures, methods of doing business, servicing clients, proposals and contracts, whether in
writing, oral or machine-readable form. Any reports, analysis or documents prepared in whole or in part by Member in connection
with providing the services hereunder or provided to the Member in connection with providing the services hereunder shall be considered
Proprietary Information. Proprietary Information does not include information in the public domain, other than information that
came into the public domain, unless as a result of the Member’s actions in violation of his/her obligations hereunder, or
information which was known to the Member prior to the date of this Agreement or was lawfully received from a third party or developed
by the Member, in each without reliance on or use of any of the Company’s Proprietary Information.

 

(b)       During
and following the Term, the Member shall maintain in confidence and use the Proprietary Information solely for the purposes of
carrying out the services hereunder and shall not disclose the Proprietary Information to any third parties or otherwise publish
information or make public statements regarding the Company, or information that contains any Proprietary Information or any derivative
thereof, in each case without the express written consent of the Company. Promptly upon request, the Member shall return to the
Company all documentary or other tangible evidence of the Proprietary Information in the Member’s possession or under the
Member’s control.

 

(c)       The
Member agrees that all intellectual property conceived, discovered, developed, or reduced to practice by the Member, solely or
in collaboration with others, during the term of this Agreement that relates to the business of the Company (collectively, “Inventions”),
are the sole property of the Company. The Member also agrees to assign (or cause to be assigned) and hereby assigns to the Company
all Inventions and all intellectual property related to all Inventions. Any assignment of Inventions or intellectual property under
this Agreement includes all rights of paternity, integrity, disclosure, and withdrawal and any other rights that may be known as
“moral rights” (collectively, “Moral Rights”). The Member hereby irrevocably waives, to the
extent permitted by applicable law, any and all claims the Member has or may later have in any jurisdiction to any Moral Right.
The Member agrees to assist the Company at the Company’s expense, to secure the Company’s rights in Inventions and
intellectual property relating to such Inventions. The Member also agrees that the Member’s obligation in this regard will
continue after the termination of this Agreement.

 

8.            Remedies.
The Member acknowledges that any breach of the provisions of Section 7 above shall result in serious and irreparable injury
to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Member agrees, therefore,
that, in addition to any remedy it may have, the Company shall be entitled to enforce the specific performance of this Agreement
by the Member and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity
of proving actual damages.

 

    	 	- 2 -	 

     

    

 

9.            Termination.
Either party may terminate this Agreement, with or without cause, at any time upon ten (10) days’ written notice to the other
party. In the event of any such termination (or in the event of Member’s death or incapacity), Member shall be entitled to
payment of any outstanding amounts due hereunder incurred prior to such termination. In the event of any such termination by Member,
Member shall, if requested to do so by the Company, complete unfinished reports or other matters upon which work has been commenced
under this Agreement and return to the Company any Proprietary Information in the Member’s possession.

 

10.          No
Conflicts. Member represents and warrants to the Company that performance of the Member’s obligations under this Agreement
does not and will not violate any written or oral agreement, under which the Member is bound.

 

11.          General
Provisions.

 

(a)       Notice.
Any notice required or permitted under this Agreement shall be given in writing to the parties at their respective addresses specified
above, or at such other address for a party as that party may specify by notice. Notice shall be effective upon receipt by the
addressee.

 

(b)       Use
of the Company’s Name. The Member shall not, without the prior written consent of the Company, use or display the Company’s
name, trademark, logo, symbol, or other image of the Company.

 

(c)       Miscellaneous.
This Agreement: (i) may be executed in two counterparts, each of which, when executed by both parties to this Agreement shall be
deemed to be an original, and all of which counterparts together shall constitute one and the same instrument; (ii) constitutes
the entire agreement of the parties with respect to its subject matter, superseding all prior oral and written communications,
proposals, negotiations, representations, understandings, courses of dealing, agreements, contracts, and the like between the parties
in such respect; (iii) may be amended, modified, or terminated, and any right under this Agreement may be waived in whole or in
part, only by a writing signed by both parties; and (iv) is not intended to inure to the benefit of any third-party beneficiaries.

 

(d)       Governing
Law; Dispute Resolution; Jurisdiction and Venue. This Agreement shall be deemed to have been made and delivered in New York
City and will be governed as to validity, interpretation, construction, effect and in all other respects by the internal law of
the State of New York. Each of the Company and the Member hereby (i) agrees that any legal suit, action or proceeding arising
out of or relating to this Agreement will be instituted exclusively in the New York State Supreme Court, County of New York, or
in the United States District Court for the Southern District of New York, (ii) waives any objection to the venue of any such
suit, action or proceeding and the right to assert that such forum is not a convenient forum for such suit, action or proceeding;
(iii) irrevocably consents to the jurisdiction of the New York State Supreme Court, County of New York, and the United States
District Court for the Southern District of New York in any such suit, action or proceeding; (iv) agrees to accept and acknowledge
service of any and all process that may be served in any such suit, action or proceeding in New York State Supreme Court, County
of New York or in the United States District Court for the Southern District of New York; and (v) agrees that service of process
upon it mailed by certified mail will be deemed in every respect effective service of process upon it in any suit, action or proceeding.

 

    	 	- 3 -	 

     

    

 

	SCOPUS BIOPHARMA INC.	 	[MEMBER]
	 	 	 	 	 
	 	 	 
	 	 	 	 	 
	Name:	 	           	Name:	 
	 	 	 	 	 
	Title:	 	 	Date:	 
	 	 	 	 	 
	Date: 		 	 	 

 

[Signature Page to Scientific Advisory Board
Member Agreement]

 

     

     

    

 

EXHIBIT A

 

OPTION AGREEMENT

 
[Signature Page to Scientific Advisory Board
Member Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]